1 1
GSK plc
0 1 2 3 4 5
4.06
2 3
Johnson & Johnson
0 1 2 3 4 5
4.03
3 7
AstraZeneca plc
0 1 2 3 4 5
3.93
4 2
Novartis AG
0 1 2 3 4 5
3.87
5 8
Merck KGaA
0 1 2 3 4 5
3.72
6 4
Pfizer Inc
0 1 2 3 4 5
3.62
7 6
Takeda Pharmaceutical Co, Ltd
0 1 2 3 4 5
3.51
8 5
Sanofi
0 1 2 3 4 5
3.47
9 13
Bayer AG
0 1 2 3 4 5
3.36
10 9
Roche Holding AG
0 1 2 3 4 5
3.23
11 10
Novo Nordisk A/S
0 1 2 3 4 5
2.97
12 11
Eisai Co, Ltd
0 1 2 3 4 5
2.95
13 12
Boehringer Ingelheim
0 1 2 3 4 5
2.93
14 14
Gilead Sciences
0 1 2 3 4 5
2.84
15 19
Bristol Myers Squibb
0 1 2 3 4 5
2.60
16 14
Astellas Pharma Inc
0 1 2 3 4 5
2.46
17 16
Daiichi Sankyo Co, Ltd
0 1 2 3 4 5
2.20
18 15
Merck & Co, Inc
0 1 2 3 4 5
2.15
19 17
AbbVie Inc
0 1 2 3 4 5
1.84
20 18
Eli Lilly & Co
0 1 2 3 4 5
1.79
0 1 2 3 4 5

In the 2021 Index, dense ranking was used. In the 2022 Index, standard competitive ranking is used. Therefore, a direct comparison with the previous ranks of AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Merck & Co, Inc (MSD) is not possible.

The ranking above shows the position and score of each company in the 2022 Index (left) and 2021 Index (right). Click on a company's name to go to its full report card.

AMR Benchmark

Assessing how pharma companies tackle drug resistance & ensure appropriate access

The 2021 Antimicrobial Resistance Benchmark featured Report Cards for 17 pharma companies with a major stake in the anti-infectives space, as well as impactful analysis of industry trends. In November 2023, the Access to Medicine Foundation followed up by zooming in on the Opportunities set out in their Report Cards, assessing where progress has been made – and where action is still required.

Large R&D-based companies

84%
GSK
Projects in the pipeline: 31
Products on the market: 51
Score breakdown
Research & Development: 93%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
81%
Pfizer
Projects in the pipeline: 13
Products on the market: 116
Score breakdown
Research & Development: 77%
Responsible Manufacturing: 80%
Appropriate Access: 80%
Stewardship: 90%
68%
Johnson & Johnson
Projects in the pipeline: 14
Products on the market: 8
Score breakdown
Research & Development: 50%
Responsible Manufacturing: 80%
Appropriate Access: 72%
Stewardship: 80%
63%
Novartis
Projects in the pipeline: 0
Products on the market: 109
Score breakdown
Research & Development: 7%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
60%
Sanofi
Projects in the pipeline: 6
Products on the market: 47
Score breakdown
Research & Development: 33%
Responsible Manufacturing: 73%
Appropriate Access: 84%
Stewardship: 60%
58%
Shionogi
Projects in the pipeline: 11
Products on the market: 8
Score breakdown
Research & Development: 70%
Responsible Manufacturing: 93%
Appropriate Access: 4%
Stewardship: 80%
57%
Otsuka
Projects in the pipeline: 4
Products on the market: 1
Score breakdown
Research & Development: 56%
Responsible Manufacturing: 43%
Appropriate Access: 60%
Stewardship: 65%
46%
MSD
Projects in the pipeline: 13
Products on the market: 19
Score breakdown
Research & Development: 47%
Responsible Manufacturing: 73%
Appropriate Access: 29%
Stewardship: 55%

Generic medicine manufacturers

71%
Aurobindo
Projects in the pipeline: 0
Products on the market: 39
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 60%
Stewardship: 87%
69%
Abbott
Projects in the pipeline: 0
Products on the market: 85
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 53%
Stewardship: 80%
67%
Viatris
Projects in the pipeline: 0
Products on the market: 87
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 72%
Stewardship: 53%
63%
Fresenius Kabi
Projects in the pipeline: 0
Products on the market: 51
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 53%
Stewardship: 80%
60%
Cipla
Projects in the pipeline: 0
Products on the market: 59
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 40%
Stewardship: 87%
60%
Teva
Projects in the pipeline: 0
Products on the market: 137
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 47%
Stewardship: 80%
47%
Sun Pharma
Projects in the pipeline: 0
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 47%
Stewardship: 60%
20%
Alkem
Projects in the pipeline: 0
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 20%
Stewardship: N/A
15%
Hainan Hailing
Projects in the pipeline: 0
Products on the market: 43
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 20%
Appropriate Access: 20%
Stewardship: N/A
Room to improve Performance so far

The Generic & Biosimilar Medicines Programme 2023: Company Profiles is the first report to be published by the Access to Medicine Foundation’s Generic & Biosimilars Medicines Programme. It assesses what five major generic and biosimilar medicine manufacturers – Cipla, Hikma, Sun Pharma, Teva, and Viatris – are doing to expand access to their essential products in low- and middle-income countries (LMICs). Collectively, these five companies have a wide portfolio of essential medicines and a well-established presence in LMICs. Given their portfolios and footprints, the actions of these companies can have a huge impact.